Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals
This invention is directed to a pharmaceutical composition for drinking water administration comprising isoxazoline compounds of formula (I) and a polysorbate surfactant and diethylene glycol monoethyl ether (transcutol); and the use of the composition to treat or prevent parasite infestations of animals.
1. A method of preventing or treating parasite infestations in animals by administering to such animal in its drinking water a pharmaceutical composition consisting essentially of fluralaner or a salt or solvate thereof, and a pharmaceutically acceptable carrier consisting essentially of ethyl lactate, diethylene glycol monoethyl ether and a polysorbate surfactant.
2. The method according to claim 1 wherein the amount of fluralaner is between 1.5 mg/ml and 100 mg/ml.
3. The method according to claim 1 wherein the ratio of diethylene glycol monoethyl ether to polysorbate surfactant is <50:50% w/w.
4. The method according to claim 1 wherein the animals are selected from pigs and poultry.
5. The method according to claim 4 wherein the animals are laying hens.
6. The method according to claim 1 wherein the parasite infestation is a mite infestation.
7. The method according to claim 6 wherein the mite infestation is an infestation with Dermanyssus sp. or Ornithonyssus sp.
8. A medicated drinking water consisting essentially of a mixture of a pharmaceutical composition consisting essentially of fluralaner or a salt or solvate thereof, and a pharmaceutically acceptable carrier consisting essentially of ethyl lactate, diethylene glycol monoethyl ether and a polysorbate surfactant and water.
9. The medicated drinking water according to claim 8 wherein the amount of fluralaner or a salt or solvate thereof is between 0.001 and 100 mg/ml.
10. A Method for preparing medicated drinking water according to claim 8 wherein the pharmaceutical composition is diluted by injecting through a dosing pump system in a water system or by mixing with water in a medication tank.
11. The medicated drinking water of claim 8 , wherein the ratio of diethylene glycol monoethyl ether to polysorbate surfactant is <50:50% w/w.